Fine needle aspiration combined with molecular biomarkers in the diagnosis of thyroid nodules

doi:10.3760/cma.j.issn.1673-422X.2013.11.011

Abstract

Abstract: The check methods of thyroid nodules include palpation, serum thyroid hormone and highfrequency ultrasound. When the diagnosis is difficult, fineneedle aspiration (FNA) is carried to differentiate benign and malignant nodules. In clinical practice, approximately 20% of FNAderived cytology reports can not meet the standard of benign or malignant. Some specific molecular biomarkers are applied to the derivative detection of FNA, which achieve considerable progress and improve the preoperative diagnostic rate.

Key words: Thyroid nodule, Biological markers, Biopsy, needle

XIE Chuan-Xin, WANG Sheng-Ying. Fine needle aspiration combined with molecular biomarkers in the diagnosis of thyroid nodules[J]. Journal of International Oncology, 2013, 40(11): 836-839.

References

［1］ Gharib H, Papini E, Paschke R, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract, 2010, 16（Suppl 1）:1-43. ［2］ Cooper DS, Doherty GM, Haugen BR, et al. Revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid, 2009, 19(11):1167-1214. ［3］ Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid, 2009, 19(11):1159-1165. ［4］ Wang CCC, Friedman L, Kennedy GC, et al. A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid, 2011, 21(3):243-251. ［5］ Saleh HA, Feng J, Tabassum F, et al. Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy. Cytojournal, 2009, 6(1):18. ［6］ Cochand-Priollet B, Dahan H, Laloi-Michelin M, et al. Immunocytochemistry with cytokeratin 19 and anti-human mesothelial cell antibody (HBME1) increases the diagnostic accuracy of thyroid fine-needle aspirations: preliminary report of 150 liquid-based fine-needle aspirations with histological control. Thyroid, 2011, 21(10):1067-1073. ［7］ Eszlinger M, Paschke R. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol Cell Endocrinol, 2010, 322(1-2): 29-37. ［8］ Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab, 2011, 96(7):2016-2026. ［9］ Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab, 2011, 96(11): 3390-3397. ［10］ Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. New Engl J Med, 2012, 367(8):705-715. ［11］ Chudova D, Wilde JI, Wang ET, et al. Molecular classification of thyroid nodules using highdimensionality genomic data. J Clin Endocrinol Metab, 2010, 95(12):5296-5304. ［12］ Haugen BR, Baloch ZW, Chudova D, et al. Development of a novel molecular classifier to accurately identify benign thyroid nodules in patients with indeterminate FNA cytology. Presented at the 14th International Thyroid Congress. Paris, France: 2010:11-16. ［13］ He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A, 2005,102(52):19075-19080. ［14］ Sheu SY, Grabellus F, Schwertheim S, et al. Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. Br J Cancer, 2009, 102(2):376-382. ［15］ Mazeh H, Mizrahi I, Halle D, et al. Development of a microRNAbased molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid, 2011, 21(2):111-118. ［16］ de la Chapelle A, Jazdzewski K. MicroRNAs in thyroid cancer. J Clin Endocrinol Metab, 2011, 96(11):3326-3336. ［17］ Starega-Roslan J, Krol J, Koscianska E, et al. Structural basis of microRNA length variety. Nucleic Acids Res, 2011, 39(1):257-268. ［18］ Chen YT, Kitabayashi N, Zhou XK, et al. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol, 2008, 21(9):1139-1146. ［19］ Milas M, Shin J, Gupta M, et al. Circulating thyrotropin receptor mRNA as a novel marker of thyroid cancer: clinical applications learned from 1758 samples. Ann Surg, 2010, 252(4):643-651. ［20］ Milas M, Barbosa GF, Mitchell J, et al. Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer. Ann Surg Oncol, 2009, 16(2):473-480.

[1]	Fan Mengsi, Lu Yaping, Yan Li. Analysis of clinicopathologic features of false negative sentinel lymph nodes in patients with endometrial cancer [J]. Journal of International Oncology, 2023, 50(5): 274-279.
[2]	Song Tongjun, Deng Rui, Fei Lei, Lei Jinhua, Cao Fengjun. Comparison of the efficacy and safety of percutaneous needle biopsy of pulmonary or pleural lesions guided by CT and ultrasound [J]. Journal of International Oncology, 2022, 49(9): 526-531.
[3]	Chen Huangjing, Zhu Pengfei, Zhang Qing, Chen Guifang, Yang Chunlin, He Ying. Comparative study on the clinical value of contrast-enhanced ultrasound- and CT-guided percutaneous puncture biopsy in peripheral lung masses [J]. Journal of International Oncology, 2022, 49(8): 459-463.
[4]	Zhuang Weitao, Qiao Guibin. Research and application of liquid biopsy based on epigenetic markers in the diagnosis and treatment of solid tumors [J]. Journal of International Oncology, 2021, 48(6): 358-361.
[5]	Tian Linghan, Zhu Ling, Liu Xin, Ye Jingwen, He Jiahui, Wang Xicai. Level of peripheral blood circulating tumor cells in lung cancer patients detected by CI-101 and its clinical significance [J]. Journal of International Oncology, 2020, 47(4): 199-204.
[6]	Ding Yu, Qiao Guibin. Research progress of liquid biopsy in early diagnosis of lung cancer [J]. Journal of International Oncology, 2019, 46(9): 548-552.
[7]	Zhang Fangyong, Wu Fan. Research progress on exosomederived noncoding RNAs in liquid biopsy of hepatocelluar carcinoma [J]. Journal of International Oncology, 2019, 46(6): 378-381.
[8]	Wang Huan, Jiang Haiping, Gao yuan, Xu Nong, Yu Xiongfei. Research progress of anti PD-1/PD-L1 immunotherapy biomarkers [J]. Journal of International Oncology, 2019, 46(1): 40-44.
[9]	LIU Hou-Jie, WAN Jing-Hai. Molecular mechanism in malignant progression of meningioma [J]. Journal of International Oncology, 2018, 45(8): 494-498.
[10]	Chen Luojun, Li Na, Tian Jingyuan, Song Qibin, Yu Jinming. Progress of circulating tumor cells in clinical application [J]. Journal of International Oncology, 2018, 45(8): 552-555.
[11]	Wang Tuo, Li Guixiang. Research progress of circulating tumor DNA detection in radiotherapy [J]. Journal of International Oncology, 2018, 45(6): 352-354.
[12]	Shi Manman, Chen Chuang, Li Zhiyu, Sun Shengrong. Tracers′ clinical application status in the sentinel lymph node biopsy of breast cancer [J]. Journal of International Oncology, 2018, 45(4): 245-249.
[13]	Huang Can, Chen Qiuyan, Zuo Feifei, Peng Chuan, Zhong Shaobin, Mai Haiqiang, Chen Mingyuan, Zou Ruhai. Diagnostic value of lymph node EBV-DNA detection in cervical lymph node metastasis of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2018, 45(3): 143-147.
[14]	Li Zhijian, He De. Research progress on liquid biopsy in pancreatic cancer [J]. Journal of International Oncology, 2018, 45(3): 180-182.
[15]	ZOU Jiang, GUO Xiao-Lan. Advances of liquid biopsy in the diagnosis and treatment of tumor [J]. Journal of International Oncology, 2018, 45(2): 107-111.